Uiuce bus model

From 2013.igem.org

(Difference between revisions)
Line 485: Line 485:
<p>Our business model has currently been implemented through the model creation phase. Next steps include cultivating relationships and licensing our technology to existing biotechnology device manufacturers.</p><br><br>
<p>Our business model has currently been implemented through the model creation phase. Next steps include cultivating relationships and licensing our technology to existing biotechnology device manufacturers.</p><br><br>
 +
 +
<img src="https://static.igem.org/mediawiki/2013/5/5b/Uiuce_timeline.png" Hspace="10" width="720" height="300" alt="pic"/></center>
</div>
</div>

Revision as of 01:42, 29 October 2013

pic

Business Model


Data

Overview


Customer Problem
The cloning process consists of several individual steps, each with its own equipment and machinery. It is complex, yet still requires a remarkable amount of human intervention. This results in errors, inconsistencies, and an overall delay in meeting significant synthetic biology milestones. Our team seeks to minimize this “human intervention” element by designing, prototyping, and commercializing an automated cloning system.



Our Solution
Our flagship product, ModuLab, is an automated system designed to optimize cloning, the underlying process of synthetic biology. The ultimate goals of ModuLab are to minimize error, maximize efficiency and provide synthetic biologists with feedback on every stage of the cloning process.